Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.
The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.
Fulgent Genetics, Inc. officer Jian Xie reported a proposed sale of 2,127 common shares, with an aggregate market value of $41,809.21 and an approximate sale date of September 2, 2026. Morgan Stanley Smith Barney LLC is named as broker. The remarks describe this sale and sales during the prior three months as sell-to-cover transactions to satisfy tax-withholding obligations, not discretionary trades.
Earlier sales listed were 2,146 shares on June 2, 2026, for gross proceeds of $38,382.27, and 1,193 shares on August 27, 2026, for gross proceeds of $23,746.99.
Fulgent Genetics, Inc. (FLGT) has a notice under Rule 144 for sales of common stock by officer Hanlin Gao. The notice covers a planned sale through Morgan Stanley Smith Barney LLC of 1,673 shares of common stock on September 2, 2026, when 27,515,293 shares were outstanding.
The shares relate to 37,790 restricted shares that vested on February 25, 2025 as equity compensation for services. Gao also reported sales of 1,688 shares on June 2, 2026 and 939 shares on August 27, 2026. All transactions are stated to be “sell to cover” for tax withholding, not discretionary trading.
Fulgent Genetics, Inc. (FLGT) reported an insider tax-withholding transaction by Chief Executive Officer and director Ming Hsieh. On 2026-08-26, 2,949 shares of common stock were withheld at $19.81 per share to satisfy tax obligations arising from the vesting of restricted stock units granted on February 26, 2024.
After this withholding, Hsieh directly held 890,344 common shares. He also has indirect holdings through The Ming Hsieh Trust, the Dynasty Trust (where he disclaims beneficial interest except for any pecuniary interest), a Uniform Transfers to Minor Act account for which he is custodian holding 1,000 shares, and 1,000 shares held by an immediate family member in the same household.
For Fulgent Genetics, Inc. (FLGT), CFO and Treasurer Paul Kim reported a Form 4 transaction involving 1,168 shares of common stock on 2026-08-26. The shares were withheld to satisfy tax withholding obligations triggered by the vesting of restricted stock units, not sold in an open-market trade. After this tax-withholding disposition, Kim’s directly held stake is 358,630 shares of common stock.
Fulgent Genetics, Inc. (FLGT) reported an insider transaction by President and COO Jian Xie. On 2026-08-27, Xie sold 1,193 shares of common stock at a weighted-average price of $19.9053 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 26, 2024. After this sale, Xie directly held 362,051 shares and had an additional 220,816 shares held indirectly through The Hsieh Family Dynasty Trust, for which he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. (FLGT) reported that Chief Scientific Officer Hanlin Gao sold 939 shares of common stock on August 27, 2026, in an open-market transaction at a weighted-average price of $19.9053 per share, in multiple trades between $19.83 and $20.00. According to the disclosure, the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 26, 2024. Following this sale, Gao directly holds 987,790 shares of Fulgent Genetics common stock.
Fulgent Genetics, Inc. (FLGT) is the issuer for a Rule 144 notice filed for the account of Hanlin Gao, an officer. The notice covers a proposed sale of 939 shares of common stock through Morgan Stanley Smith Barney LLC. These shares relate to equity compensation, including restricted stock/RSUs that vested on February 26, 2024, from which 21,146 shares were acquired.
The filer also reports prior sales in the last three months of 945 shares and 1,688 shares of FLGT common stock. According to the statement, the current proposed sale and recent sales were executed as "sell to cover" transactions to satisfy tax withholding obligations tied to RSU vesting, and are described as not representing discretionary trades by the reporting person.
Fulgent Genetics, Inc. (FLGT) received a notice under Rule 144 that Jian Xie plans to sell 1,193 shares of common stock through Morgan Stanley Smith Barney LLC. The shares derive from 25,350 shares of restricted stock that vested on February 26, 2024 as equity compensation.
The filing states that this planned sale and prior sales over the past three months were made under "sell to cover" transactions to satisfy tax withholding obligations related to Restricted Stock Units, and are not discretionary trades by the reporting person. Fulgent Genetics had 27,515,293 shares of common stock outstanding as of August 27, 2026.
Fulgent Genetics reported second quarter 2026 results with revenue of $85.4 million, up from $81.8 million a year earlier, and a GAAP net loss of $29.5 million, or $(1.05) per share. GAAP gross margin was 30.1%, non-GAAP gross margin 31.3%, and non-GAAP net loss $16.2 million.
The company repurchased approximately 1.5 million shares for $23.8 million in the quarter and ended with $551.5 million in cash, cash equivalents, restricted cash and marketable securities, excluding an anticipated $106.1 million tax refund. For 2026, management guides revenue to $330–$340 million, non-GAAP loss of $63–$67 million, non-GAAP loss per share of $2.22–$2.35 and year-end cash of about $610 million. Management linked the guidance revision to processing delays during the final phase of its billing and revenue cycle transition that affected collection rates.
In its therapeutics segment, Fulgent highlighted Phase 2 data for FID‑007 in recurrent/metastatic head and neck cancer, with an objective response rate of 61.9%, one-year overall survival of 63.4%, a manageable safety profile, and plans to advance to a Phase 3 study.